Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Tuberculous Meningitis Treatment Market Snapshot (2023 to 2033)

The global tuberculous meningitis treatment market garnered a market value of US$ 150 Billion in 2023 and is expected to accumulate a market value of US$ 300 Billion by registering a CAGR of 7.2% in the forecast period 2023 to 2033.

Rising tuberculous meningitis incidences and the rising need for novel diagnostic technologies for precise diagnosis are projected to boost the growth of the tuberculous meningitis treatment market. Growing demand for point-of-care (PoC) services is expected to boost market expansion in the future years since PoC services give high-accuracy results in less time than traditional techniques.

Tuberculous meningitis, widely known as TB meningitis or tubercular meningitis, is a kind of bacterial meningitis caused by Mycobacterium tuberculosis infection of the meninges (the membranes that surround the central nervous system). The primary symptoms are fever and headache; disorientation appears later, and coma has a terrible prognosis. Meningism is missing in one-fifth of TB meningitis patients. Patients may experience localized neurological impairments as well.

The predominant characteristic is Mycobacterium tuberculosis of the meninges, with inflammation concentrated at the base of the brain. Cranial nerve roots may be impacted when inflammation occurs in the brain stem subarachnoid region. The symptoms will be similar to those of lesions that occupy space.

Blood-borne transmission occurs, probably by crossing the blood-brain barrier; nevertheless, a proportion of patients may acquire TB meningitis through a cortical focus rupture in the brain an even smaller proportion gets it via a bone focus rupture in the spine. Isoniazid, rifampicin, pyrazinamide, and ethambutol are used to treat TB meningitis for two months, followed by isoniazid and rifampicin alone for ten months. Steroids help minimize the chance of mortality in people who do not have HIV.

During the first six weeks of therapy, steroids can be administered. Some persons may require immunomodulatory drugs like thalidomide. About one-third of persons with TB meningitis develop hydrocephalus as a consequence. Aspirin may decrease or postpone death, presumably by lowering complications such as infarcts. The expanding elderly population, which is contributing to an increase in incidences of meningitis, is expected to fuel market demand.

Data Points Key Statistics
Expected Market Value (2023) US$ 150 Billion
Anticipated Forecast Value (2033) US$ 300 Billion
Projected Growth Rate (2023 to 2033) 7.2% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Tuberculous Meningitis Treatment Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for tuberculous meningitis treatment is projected to increase at a CAGR of 7.2% during the forecast period between 2023 and 2033, reaching a total of US$ 300 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 6.4%.

In the future years, the growing need for point-of-care services is expected to fuel expansion in the worldwide tuberculous meningitis treatment market. When compared to traditional meningitis diagnostic testing procedures, point-of-care services provide more exact findings in less time.

Increased tuberculous meningitis prevalence is expected to boost growth in the worldwide market in the near future. However, the presence of a complicated and demanding regulatory environment may impede the growth of the worldwide tuberculous meningitis treatment market in the future years.

Which are Some Prominent Drivers of Tuberculous Meningitis Treatment Market?

Tuberculous Meningitis Treatment Industry will be Driven by Technological Advancements to Battle Infectious Illnesses

The collaboration of the public and private sectors to enhance vaccine access to the populace is a major driving force for the expansion of the tuberculous meningitis treatment market. For example, the Global Alliance for Vaccines and Immunization (GAVIs) is an international organization that brings together the public and commercial sectors with the purpose of providing children in the world's poorest nations with access to all the newest vaccines. People with immune-compromised conditions such as HIV, cancer, diabetes, and organ transplants are more likely to get aseptic meningitis.

Advances in diagnostics and technology platforms have contributed to the expansion of the tuberculous meningitis treatment industry. For example, in 2009, Cadila formed a partnership with Novavax, a vaccine business located in the USA, to research and manufacture therapeutic and preventative vaccines to battle infectious illnesses. The introduction of a new vaccine with an enhanced mechanism, as well as advances in genetics and immunology, are projected to drive the tuberculous meningitis treatment industry forward.

Which are the Trough Areas faced by the Tuberculous Meningitis Treatment Market?

High Cost of the Treatment to Stifle Market Growth

Stringent regulatory laws, as well as traditional religious views in several major market nations, are creating substantial barriers to worldwide tuberculous meningitis treatment market expansion. The intricate nature of the therapy and the high cost connected with it limits the market for tuberculous meningitis treatment.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Region-Wise Insights

How will Tuberculous Meningitis Treatment Market Demand progress in the Asia Pacific?

Increasing Prevalence of Tuberculous Meningitis to Widening Profit Margins

According to the World Health Organization, Asia Pacific was the main market for tuberculous meningitis treatment in 2016 due to reasons such as increased tuberculosis meningitis prevalence. Due to the enormous population bases in some of the region's main nations, such as India and China, the Asia Pacific worldwide tuberculous meningitis treatment market is expected to rise at the fastest rate over the projected period.

Increased patient awareness as well as the development of laboratory infrastructure in the area is projected to support Asia Pacific's growth in the worldwide market in the near future. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 6.5% in the assessment period 2023 to 2033.

How attractive are Growth Prospects for Tuberculous Meningitis Treatment in North America?

A Dynamic Reimbursement Landscape to Drive Market Growth

Throughout the projection period of 2023 to 2033, North America will be the quickest market for tuberculous meningitis treatment. The Centers for Disease Control and Prevention reported 9,421 TB cases in 2014, with a rate of 2.96 infections per 100,000 people.

The increased prevalence of tuberculous meningitis, a dynamic reimbursement landscape, and sophisticated healthcare infrastructure are driving market expansion. North America is expected to grow at a CAGR of 6.9% in the assessment period 2023 to 2033.

What Factors favoring the Growth of Tuberculous Meningitis Treatment in Europe?

Supporting Regulatory Approval fuelling the Market in Europe

According to the World Health Organization (WHO), 32,000 patient fatalities occurred in Europe in 2015. The incidence of tuberculous meningitis in Eastern European nations, as well as supporting regulatory approval, is driving the expansion of the tuberculous meningitis treatment industry. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 6.7% in the forecast period 2023 to 2033.

Category-Wise Insights

Which is the Most Preferred Treatment Segment in the Tuberculous Meningitis Treatment Market?

The Adjunctive Corticosteroid Therapy Segment to enhance Sales Prospects

The increasing frequency of chronic illnesses, the expanding geriatric population, and increased investment in research & development are the primary driving factors driving the expansion of the adjunctive corticosteroid therapy segment further driving the market growth.

Which End User Segment is Gaining the Most Traction in the Tuberculous Meningitis Treatment Market?

The Hospital Segment is Gaining the Most Traction in the Market

The end-user segment is divided into hospitals, specialty clinics, and others in the tuberculous meningitis treatment market. In 2022, the hospital sector accounted for the highest proportion of the worldwide market, and this trend is anticipated to continue over the assessment period. This rise can be linked to an increase in the number of foreign hospitals with technologically advanced laboratory facilities.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Start-ups for Tuberculous Meningitis Treatment Market

Key start-up players in the tuberculous meningitis treatment are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key tuberculous meningitis treatment start-ups are as follows:

  • Plasmonic Diagnostics is a firm located in the USA that is developing diagnostics for infectious illnesses. Lipoarabinomannan (LAM) is detected in urine samples by the startup's non-invasive and low-cost molecular testing method. The test has a high sensitivity since it is based on the fluorescent sandwich enzyme-linked immunosorbent assay (ELISA). It also shortens the time to detection for tuberculosis and can be used to identify other infectious disorders.
  • Arkangel AI, a Canadian business, analyses chest X-ray images using deep learning. The startup's solution diagnoses pulmonary TB, as well as other respiratory disorders like COVID-19, edema, fibrosis, and pneumothorax, in seconds with a single X-ray scan. The startup's approach can also detect parasite and ocular diseases using blood samples and fundus photos. The startup's technology improves patient outcomes by detecting avoidable illnesses early.
  • Quratis is a South Korean business that is developing a revolutionary tuberculosis vaccine. QTP101, the startup's subunit vaccine, targets numerous antigens linked to virulence and latency. It makes use of the company's own cell-penetrating peptide (CPP) platform and peptide nucleic acid (PNA) technology. Quratis has established the effectiveness of QTP101 as a BCG booster vaccination in animal models.
  • Astrego, a Swedish firm, provides in-vitro diagnostics solutions to combat antimicrobial resistance. For quick screening, the startup's PA-100 system employs desktop equipment and customized panels. The automated approach prescribes tailored antibiotics for TB, urinary tract infections, respiratory disorders, and sepsis.
  • Everwell, an Indian firm, creates HealthTech products to improve patient adherence. 99DOTS, the startup's digital adherence system, encourages patients to take their drugs on a regular basis by using low-cost packaging with concealed codes. The patient must register daily adherence by sending the concealed code via a toll-free phone number, SMS, or other methods. To encourage adherence, Everwell also provides Video-Observed Therapy (VOT) and evriMED, a medicine reminder.

Market Competition

Key players in the tuberculous meningitis treatment market are Pfizer, GSK, Sanofi, Novartis, Merck & Co, AstraZeneca, Biomed Pvt. Ltd, K.T.Z Company Limited, Sumitomo, and Baxter.

Recent Developments:

  • In January 2023, Baxter International Inc., a leading global medtech firm announced a comprehensive strategic plan to increase operational efficiencies, boost long-term performance, accelerate innovation, and create extra value for all stakeholders. These changes include the company's plan to spin off its Renal Care and Acute Therapies global business units (GBUs) into a separate, publicly traded company; a simplified commercial and manufacturing footprint to improve underlying business performance; and additional portfolio actions to improve Baxter's capital structure, including a review of strategic alternatives for the BioPharma Solutions (BPS) business.
  • In December 2022, Pfizer Inc. said that the FDA has accepted for consideration a Biologics License Application (BLA) for its experimental pentavalent meningococcal vaccination candidate (MenABCWY). MenABCWY was filed by Pfizer for the prevention of meningococcal illness caused by the most frequent serogroups in people aged 10 to 25.
  • In November 2022, GSK plc announced positive Phase IIa study results showing that GSK3036656, a first-in-class investigational antitubercular agent, was well tolerated and demonstrated early bactericidal activity with a low, once-daily oral dose after 14 days of treatment in participants with drug-susceptible pulmonary tuberculosis. These findings suggest that GSK3036656 has the potential to be a component of simpler treatment regimens in the future, which might aid in the fight against tuberculosis.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 150 Billion
Market Value in 2033 US$ 300 Billion
Growth Rate CAGR of 7.2% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Treatment
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • India
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Pfizer Inc.
  • GSK Inc.
  • Sanofi S.A
  • Novartis A.G
  • Merck & Co.
  • AstraZeneca Plc.
  • Biomed Pvt. Ltd
  • K.T.Z Company Limited
  • Sumitomo Group
  • Baxter International
Customization Available Upon Request

Key Segments Profiled in the Tuberculous Meningitis Treatment Market Survey

By Treatment:

  • Antibiotic Therapy
  • Adjunctive Corticosteroid Therapy
  • Neurosurgical Management

By End User:

  • Hospitals
  • Specialty Clinics
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

How Much Revenue is Generated from Adoption of Tuberculosis Meningitis Treatment?

In 2023, the demand for tuberculosis meningitis treatments could generate US$ 150 billion revenue.

What is the Global Advancement Rate for Adoption of Tuberculosis Meningitis Treatments?

The global adoption of tuberculosis meningitis treatments is poised to witness 7.2% CAGR through 2033.

Which Type of Tuberculosis Meningitis Treatment Garners Higher Revenue ?

The adjunctive corticosteroid therapy segment garners higher revenue than other treatment types.

What Will be the Growth Rate of the Market in North America?

The market in North America may witness 6.9% CAGR until 2033.

What is the Scope of Growth for Europe Tuberculosis Meningitis Treatment Market?

The demand in Europe is poised to record at 6.7% CAGR through 2033.

Table of Content

1. Executive Summary | Tuberculous Meningitis Treatment Market

        1.1. Global Market Outlook

        1.2. Demand-side Trends

        1.3. Supply-side Trends

        1.4. Technology Roadmap Analysis

        1.5. Analysis and Recommendations

2. Market Overview

        2.1. Market Coverage / Taxonomy

        2.2. Market Definition / Scope / Limitations

3. Market Background

        3.1. Market Dynamics

            3.1.1. Drivers

            3.1.2. Restraints

            3.1.3. Opportunity

            3.1.4. Trends

        3.2. Scenario Forecast

            3.2.1. Demand in Optimistic Scenario

            3.2.2. Demand in Likely Scenario

            3.2.3. Demand in Conservative Scenario

        3.3. Opportunity Map Analysis

        3.4. Investment Feasibility Matrix

        3.5. PESTLE and Porter’s Analysis

        3.6. Regulatory Landscape

            3.6.1. By Key Regions

            3.6.2. By Key Countries

        3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

        4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

        4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

            4.2.1. Y-o-Y Growth Trend Analysis

            4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

        5.1. Introduction / Key Findings

        5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

        5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

            5.3.1. Antibiotic Therapy

            5.3.2. Adjunctive Corticosteroid Therapy

            5.3.3. Neurosurgical Management

        5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

        5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users

        6.1. Introduction / Key Findings

        6.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022

        6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033

            6.3.1. Hospitals

            6.3.2. Specialty Clinics

            6.3.3. Others

        6.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022

        6.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

        7.1. Introduction

        7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

        7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

            7.3.1. North America

            7.3.2. Latin America

            7.3.3. Europe

            7.3.4. Asia Pacific

            7.3.5. Middle East and Africa (MEA)

        7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            8.2.1. By Country

                8.2.1.1. USA

                8.2.1.2. Canada

            8.2.2. By Treatment

            8.2.3. By End Users

        8.3. Market Attractiveness Analysis

            8.3.1. By Country

            8.3.2. By Treatment

            8.3.3. By End Users

        8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            9.2.1. By Country

                9.2.1.1. Brazil

                9.2.1.2. Mexico

                9.2.1.3. Rest of Latin America

            9.2.2. By Treatment

            9.2.3. By End Users

        9.3. Market Attractiveness Analysis

            9.3.1. By Country

            9.3.2. By Treatment

            9.3.3. By End Users

        9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            10.2.1. By Country

                10.2.1.1. Germany

                10.2.1.2. UK

                10.2.1.3. France

                10.2.1.4. Spain

                10.2.1.5. Italy

                10.2.1.6. Rest of Europe

            10.2.2. By Treatment

            10.2.3. By End Users

        10.3. Market Attractiveness Analysis

            10.3.1. By Country

            10.3.2. By Treatment

            10.3.3. By End Users

        10.4. Key Takeaways

11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            11.2.1. By Country

                11.2.1.1. China

                11.2.1.2. Japan

                11.2.1.3. South Korea

                11.2.1.4. Singapore

                11.2.1.5. Thailand

                11.2.1.6. Indonesia

                11.2.1.7. Australia

                11.2.1.8. New Zealand

                11.2.1.9. Rest of Asia Pacific

            11.2.2. By Treatment

            11.2.3. By End Users

        11.3. Market Attractiveness Analysis

            11.3.1. By Country

            11.3.2. By Treatment

            11.3.3. By End Users

        11.4. Key Takeaways

12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            12.2.1. By Country

                12.2.1.1. GCC Countries

                12.2.1.2. South Africa

                12.2.1.3. Israel

                12.2.1.4. Rest of MEA

            12.2.2. By Treatment

            12.2.3. By End Users

        12.3. Market Attractiveness Analysis

            12.3.1. By Country

            12.3.2. By Treatment

            12.3.3. By End Users

        12.4. Key Takeaways

13. Key Countries Market Analysis

        13.1. USA

            13.1.1. Pricing Analysis

            13.1.2. Market Share Analysis, 2022

                13.1.2.1. By Treatment

                13.1.2.2. By End Users

        13.2. Canada

            13.2.1. Pricing Analysis

            13.2.2. Market Share Analysis, 2022

                13.2.2.1. By Treatment

                13.2.2.2. By End Users

        13.3. Brazil

            13.3.1. Pricing Analysis

            13.3.2. Market Share Analysis, 2022

                13.3.2.1. By Treatment

                13.3.2.2. By End Users

        13.4. Mexico

            13.4.1. Pricing Analysis

            13.4.2. Market Share Analysis, 2022

                13.4.2.1. By Treatment

                13.4.2.2. By End Users

        13.5. Germany

            13.5.1. Pricing Analysis

            13.5.2. Market Share Analysis, 2022

                13.5.2.1. By Treatment

                13.5.2.2. By End Users

        13.6. UK

            13.6.1. Pricing Analysis

            13.6.2. Market Share Analysis, 2022

                13.6.2.1. By Treatment

                13.6.2.2. By End Users

        13.7. France

            13.7.1. Pricing Analysis

            13.7.2. Market Share Analysis, 2022

                13.7.2.1. By Treatment

                13.7.2.2. By End Users

        13.8. Spain

            13.8.1. Pricing Analysis

            13.8.2. Market Share Analysis, 2022

                13.8.2.1. By Treatment

                13.8.2.2. By End Users

        13.9. Italy

            13.9.1. Pricing Analysis

            13.9.2. Market Share Analysis, 2022

                13.9.2.1. By Treatment

                13.9.2.2. By End Users

        13.10. China

            13.10.1. Pricing Analysis

            13.10.2. Market Share Analysis, 2022

                13.10.2.1. By Treatment

                13.10.2.2. By End Users

        13.11. Japan

            13.11.1. Pricing Analysis

            13.11.2. Market Share Analysis, 2022

                13.11.2.1. By Treatment

                13.11.2.2. By End Users

        13.12. South Korea

            13.12.1. Pricing Analysis

            13.12.2. Market Share Analysis, 2022

                13.12.2.1. By Treatment

                13.12.2.2. By End Users

        13.13. Singapore

            13.13.1. Pricing Analysis

            13.13.2. Market Share Analysis, 2022

                13.13.2.1. By Treatment

                13.13.2.2. By End Users

        13.14. Thailand

            13.14.1. Pricing Analysis

            13.14.2. Market Share Analysis, 2022

                13.14.2.1. By Treatment

                13.14.2.2. By End Users

        13.15. Indonesia

            13.15.1. Pricing Analysis

            13.15.2. Market Share Analysis, 2022

                13.15.2.1. By Treatment

                13.15.2.2. By End Users

        13.16. Australia

            13.16.1. Pricing Analysis

            13.16.2. Market Share Analysis, 2022

                13.16.2.1. By Treatment

                13.16.2.2. By End Users

        13.17. New Zealand

            13.17.1. Pricing Analysis

            13.17.2. Market Share Analysis, 2022

                13.17.2.1. By Treatment

                13.17.2.2. By End Users

        13.18. GCC Countries

            13.18.1. Pricing Analysis

            13.18.2. Market Share Analysis, 2022

                13.18.2.1. By Treatment

                13.18.2.2. By End Users

        13.19. South Africa

            13.19.1. Pricing Analysis

            13.19.2. Market Share Analysis, 2022

                13.19.2.1. By Treatment

                13.19.2.2. By End Users

        13.20. Israel

            13.20.1. Pricing Analysis

            13.20.2. Market Share Analysis, 2022

                13.20.2.1. By Treatment

                13.20.2.2. By End Users

14. Market Structure Analysis

        14.1. Competition Dashboard

        14.2. Competition Benchmarking

        14.3. Market Share Analysis of Top Players

            14.3.1. By Regional

            14.3.2. By Treatment

            14.3.3. By End Users

15. Competition Analysis

        15.1. Competition Deep Dive

            15.1.1. Pfizer

                15.1.1.1. Overview

                15.1.1.2. Product Portfolio

                15.1.1.3. Profitability by Market Segments

                15.1.1.4. Sales Footprint

                15.1.1.5. Strategy Overview

                    15.1.1.5.1. Marketing Strategy

            15.1.2. GSK

                15.1.2.1. Overview

                15.1.2.2. Product Portfolio

                15.1.2.3. Profitability by Market Segments

                15.1.2.4. Sales Footprint

                15.1.2.5. Strategy Overview

                    15.1.2.5.1. Marketing Strategy

            15.1.3. Sanofi

                15.1.3.1. Overview

                15.1.3.2. Product Portfolio

                15.1.3.3. Profitability by Market Segments

                15.1.3.4. Sales Footprint

                15.1.3.5. Strategy Overview

                    15.1.3.5.1. Marketing Strategy

            15.1.4. Novartis

                15.1.4.1. Overview

                15.1.4.2. Product Portfolio

                15.1.4.3. Profitability by Market Segments

                15.1.4.4. Sales Footprint

                15.1.4.5. Strategy Overview

                    15.1.4.5.1. Marketing Strategy

            15.1.5. Merck & Co

                15.1.5.1. Overview

                15.1.5.2. Product Portfolio

                15.1.5.3. Profitability by Market Segments

                15.1.5.4. Sales Footprint

                15.1.5.5. Strategy Overview

                    15.1.5.5.1. Marketing Strategy

            15.1.6. AstraZeneca

                15.1.6.1. Overview

                15.1.6.2. Product Portfolio

                15.1.6.3. Profitability by Market Segments

                15.1.6.4. Sales Footprint

                15.1.6.5. Strategy Overview

                    15.1.6.5.1. Marketing Strategy

            15.1.7. Biomed Pvt. Ltd

                15.1.7.1. Overview

                15.1.7.2. Product Portfolio

                15.1.7.3. Profitability by Market Segments

                15.1.7.4. Sales Footprint

                15.1.7.5. Strategy Overview

                    15.1.7.5.1. Marketing Strategy

            15.1.8. K.T.Z Company Limited

                15.1.8.1. Overview

                15.1.8.2. Product Portfolio

                15.1.8.3. Profitability by Market Segments

                15.1.8.4. Sales Footprint

                15.1.8.5. Strategy Overview

                    15.1.8.5.1. Marketing Strategy

            15.1.9. Sumitomo

                15.1.9.1. Overview

                15.1.9.2. Product Portfolio

                15.1.9.3. Profitability by Market Segments

                15.1.9.4. Sales Footprint

                15.1.9.5. Strategy Overview

                    15.1.9.5.1. Marketing Strategy

            15.1.10. Baxter

                15.1.10.1. Overview

                15.1.10.2. Product Portfolio

                15.1.10.3. Profitability by Market Segments

                15.1.10.4. Sales Footprint

                15.1.10.5. Strategy Overview

                    15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Recommendations

Healthcare

Meningococcal Vaccine Market

Published : May 2024

Healthcare

Tuberculosis Therapeutics Market

Published : December 2022

Healthcare

Meningitis Treatment Market

Published : November 2022

Explore Healthcare Insights

View Reports

Tuberculous Meningitis Treatment Market